Maze Therapeutics (MAZE) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $1.89B
- As of Nov 13, 2026
- P/E
- -12.50x
- Trailing twelve months
- P/B
- 4.40x
- Latest reported equity
- P/S
- 11.24x
- Trailing twelve months
- ROE
- -35.2%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $1.89B
- As of Nov 13, 2026
- P/E
- -12.50x
- Trailing twelve months
- P/B
- 4.40x
- Latest reported equity
- P/S
- 11.24x
- Trailing twelve months
- ROE
- -35.2%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-12.50x
Net loss — not comparable
P/B
4.40x
P/S
11.24x
Earnings and dividend metrics▾
Earnings
EPS
-$2.75
Earnings per share
BPS
$7.80
Book value per share
ROE
-35.2%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $2.75 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $7.80 of net assets.
- ROE — shareholder equity shrank by 35.2% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Operating income decreased from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Operating income · same quarter, three years
Year-ago quarter -$33MDown
—
FY24 Q3
-$33M
Jul–Sep '25
-$52M
Jul–Sep '26
Blank bars mark quarters with no figure found in the filings.
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 9, 2026.
- Earnings per share decreased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Operating income decreased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Net income decreased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
Filed Nov 9, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Coloma Jason VChief Executive Officer · Nov 2, 2026Open-market sale34,501 shares · $1.0MAvg. price $30.2532
Show 4 price lots
- 26,563 shares × $30.095$799K
- 5,345 shares × $31.0528$166K
- 2,257 shares × $30.1241$68K
- 336 shares × $30.9089$10K
- Dandekar AtulCSBO · Oct 29, 2026Open-market sale7,500 shares · $241KAvg. price $32.070932,316 shares held after
- Dandekar AtulCSBO · Oct 29, 2026Option exercise7,500 shares · $78KAvg. price $10.42
Show 2 price lots
- 6,643 shares × $10.42$69K
- 857 shares × $10.42$9K
- Coloma Jason VChief Executive Officer · Oct 1, 2026Open-market sale34,501 shares · $932KAvg. price $27.0212
Show 2 price lots
- 31,908 shares × $27.021$862K
- 2,593 shares × $27.0241$70K
- Bernstein HaroldPresident, R&D & CMO · Oct 1, 2026Open-market sale16,141 shares · $435KAvg. price $26.93410 shares held after
- Bernstein HaroldPresident, R&D & CMO · Oct 1, 2026Option exercise16,141 shares · $168KAvg. price $10.4216,141 shares held after
- Dandekar AtulCSBO · Sep 29, 2026Open-market sale7,500 shares · $203KAvg. price $27.056132,316 shares held after
- Dandekar AtulCSBO · Sep 29, 2026Option exercise7,500 shares · $78KAvg. price $10.4239,816 shares held after
- Bernstein HaroldPresident, R&D & CMO · Sep 4, 2026Open-market sale9,705 shares · $255KAvg. price $26.22380 shares held after
- Coloma Jason VChief Executive Officer · Sep 3, 2026Open-market sale11,411 shares · $297KAvg. price $26.0106
Show 2 price lots
- 11,282 shares × $26.0133$293K
- 129 shares × $25.7749$3K
- Bernstein HaroldPresident, R&D & CMO · Sep 3, 2026Open-market sale5,189 shares · $135KAvg. price $26.0106
Show 2 price lots
- 5,130 shares × $26.0133$133K
- 59 shares × $25.78$2K
- Dandekar AtulCSBO · Sep 3, 2026Open-market sale3,243 shares · $84KAvg. price $26.011
Show 2 price lots
- 3,207 shares × $26.0133$83K
- 36 shares × $25.81$929
- Courtney PhillipsGC and Corp. Secretary · Sep 3, 2026Open-market sale2,012 shares · $52KAvg. price $26.0108
Show 2 price lots
- 1,990 shares × $26.0133$52K
- 22 shares × $25.78$567
- Coloma Jason VChief Executive Officer · Sep 2, 2026Open-market sale11,227 shares · $297KAvg. price $26.4673
Show 2 price lots
- 9,852 shares × $26.376$260K
- 1,375 shares × $27.1211$37K
- Bernstein HaroldPresident, R&D & CMO · Sep 2, 2026Open-market sale5,106 shares · $135KAvg. price $26.4672
Show 2 price lots
- 4,481 shares × $26.376$118K
- 625 shares × $27.1211$17K
- Dandekar AtulCSBO · Sep 2, 2026Open-market sale3,191 shares · $84KAvg. price $26.4673
Show 2 price lots
- 2,800 shares × $26.376$74K
- 391 shares × $27.1211$11K
- Courtney PhillipsGC and Corp. Secretary · Sep 2, 2026Open-market sale1,981 shares · $52KAvg. price $26.4674
Show 2 price lots
- 1,738 shares × $26.376$46K
- 243 shares × $27.1211$7K
- Coloma Jason VChief Executive Officer · Sep 1, 2026Open-market sale34,501 shares · $907KAvg. price $26.2891
Show 2 price lots
- 31,908 shares × $26.2876$839K
- 2,593 shares × $26.307$68K
- Bernstein HaroldPresident, R&D & CMO · Sep 1, 2026Open-market sale16,141 shares · $426KAvg. price $26.36220 shares held after
- Bernstein HaroldPresident, R&D & CMO · Sep 1, 2026Option exercise36,141 shares · $168KAvg. price $4.6537
Show 2 price lots
- 16,141 shares × $10.42$168K
- 20,000 shares × $0$0
- Dandekar AtulCSBO · Sep 1, 2026Option exercise12,500 shares · $0Avg. price $038,750 shares held after
- Courtney PhillipsGC and Corp. Secretary · Sep 1, 2026Option exercise11,000 shares · $0Avg. price $011,000 shares held after
- Coloma Jason VChief Executive Officer · Sep 1, 2026Option exercise50,000 shares · $0Avg. price $050,000 shares held after
- Dandekar AtulCSBO · Aug 28, 2026Open-market sale7,500 shares · $207KAvg. price $27.576526,250 shares held after
- Dandekar AtulCSBO · Aug 28, 2026Option exercise7,500 shares · $78KAvg. price $10.4233,750 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Maze Therapeutics (MAZE) stock information
NASDAQ
Maze Therapeutics (MAZE) is listed on NASDAQ. Its market capitalization is about $1.9B. On trailing-twelve-month earnings the P/E ratio is -12.5, and the P/B ratio is 4.4. Return on equity is -35.2%. These figures are computed in-house from official filings and are reference information only.
Maze Therapeutics — frequently asked questions
- What is the P/E ratio of Maze Therapeutics (MAZE)?
- On a trailing-twelve-month basis, MAZE trades at a P/E ratio of -12.5. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Maze Therapeutics?
- MAZE has a market capitalization of about $1.9B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.